Rovalpituzumab Biosimilar, N297A Mutant | C108P.NA

Catalog No.	C108P.NA
Product Name	Rovalpituzumab Biosimilar, N297A Mutant | C108P.NA
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Delta-Like 3 Protein
Summary	Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype	Human IgG1 kappa.
Source/Host	The anti-human DLL3 monoclonal antibody rovalpituzumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade rovalpituzumab biosimilar specifically binds to the human DLL3 protein.
Form Of Antibody	0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The Rovalpituzumab Biosimilar, N297A Mutant is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade rovalpituzumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Orleave a message with a formal purchase order (PO) Or credit card.

Description

C108P.NA: Rovalpituzumab Biosimilar, N297A Mutant
Recombinant Humanized IgG1 Monoclonal Antibody.

Background

What is rovalpituzumab biosimilar research grade? Rovalpituzumab is a humanized IgG1-kappa monoclonal antibody against the human Delta-like 3 protein (DLL3), which is an atypical Notch ligand that has been implicated in regulation of cell development and cell fate decisions, and is a downstream target of achaetescute homolog-1 (ASCL1), suggesting its role in neuroendocrine tumorigenesis. DLL3 is expressed in more than 80% of patients with small-cell lung cancer (SCLC) and other neuroendocrine tumors, but has little to no expression in normal tissues or non-neuroendocrine tumor types. DLL3 expression appears to be stable over time in SCLC tumors pre- and post-chemotherapy. Although DLL3 is mostly found within the Golgi apparatus under physiological conditions, it may reach the cell surface in case of overexpression and lead to Notch inhibition in cis. Rovalpituzumab tesirine (Rova-T) is a first-in-class antibody–drug conjugate (ADC) against DLL3, and composed of SC16, a humanized IgG1 antibody against DLL3, conjugated to the cytotoxic pyrrolobenzodiazepine (PBD) dimer D6.5 (SC-DR002) via a protease-cleavable linker. Rova-T selectively binds to DLL3 on target-expressing cells, is internalized, and upon proteolytic cleavage releases the toxin. PBD dimers then bind to the DNA minor groove where they form covalent adducts causing stalling of the replication forks, cell-cycle arrest at the G2–M boundary, and apoptosis. Rovalpituzumab biosimilar uses the same protein sequences as the therapeutic antibody rovalpituzumab.

Syd Labs provides the following research grade antibody biosimilars used in ADCs:
Tusamitamab biosimilar, research grade, anti-human CEACAM5 monoclonal antibody
Rovalpituzumab biosimilar, research grade, anti-human DLL3 monoclonal antibody
Trastuzumab biosimilar, research grade, anti-human HER2 monoclonal antibody
Cofetuzumab biosimilar, research grade, anti-human PTK7 monoclonal antibody
Ifinatamab biosimilar, research grade, anti-human B7-H3 (CD276) monoclonal antibody
Sacituzumab biosimilar, research grade, anti-human Trop-2 monoclonal antibody
Gemtuzumab biosimilar, research grade, anti-human CD33 monoclonal antibody
Polatuzumab biosimilar, research grade, anti-human CD79B monoclonal antibody
Cetuximab biosimilar, research grade, anti-human EGFR monoclonal antibody

Please remember our product information: Rovalpituzumab Biosimilar, N297A Mutant: C108P.NA Syd Labs

No more offers for this product!